OA10.03 Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up

Authors:
  • JSJ. Sands
    J. Sands
  • BCB.C. Cho
    B.C. Cho
  • MAM.-J. Ahn
    M.-J. Ahn
  • MRM. Reck
    M. Reck
  • JBJ. Bustamante-Alvarez
    J. Bustamante-Alvarez
  • HHH.-D. Hummel
    H.-D. Hummel
  • HAH. Akamatsu
    H. Akamatsu
  • MJM.L. Johnson
    M.L. Johnson
  • EFE. Felip
    E. Felip
  • SHS. Handzhiev
    S. Handzhiev
  • IKI. Korantzis
    I. Korantzis
  • HIH. Izumi
    H. Izumi

Abstract
No abstract available